Phase 3 trial comparing SB15 to aflibercept for nAMD shows promising results

The phase 3 trial evaluating SB15, a treatment for neovascular age-related macular degeneration (nAMD), has shown promising results. The study compared the efficacy, safety, pharmacokinetics, and immunogenicity of SB15 to the reference drug aflibercept (AFL) and also assessed the outcomes of switching from AFL to SB15. The results indicate that...